 (1).png "Eli Lilly & Co (NYSE: LLY)")
In a report issued on January 18, Geoff Meacham from Barclays maintained a Buy rating on Eli Lilly & Co (LLY), with a price target of $130. The company’s shares closed on Friday at $116.59, close to its 52-week high of $119.84.
According to TipRanks.com, Meacham is a 4-star analyst with an average return of 5.1% and a 54.7% success rate. Meacham covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Bausch Health Companies Inc, and Vertex Pharmaceuticals.
Currently, the analyst consensus on Eli Lilly & Co is a Moderate Buy with an average price target of $122.56, representing a 5.1% upside. In a report issued on January 7, Cantor Fitzgerald also maintained a Buy rating on the stock with a $128 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $119.84 and a one-year low of $73.69. Currently, Eli Lilly & Co has an average volume of 4.79M.
Based on the recent corporate insider activity of 131 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
